Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:47:36 2024-05-15 pm EDT			5-day change	1st Jan Change
2.76 ^USD	+3.37%		+8.24%	+217.24%

May. 10	Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	Kiromic BioPharma, Inc. announced that it has received $2 million in funding	CI

Kiromic Biopharma, Inc. Enters into an Executive Agreement with Michael Ryan to Be its Chief Technology Officer

July 08, 2021 at 01:44 pm EDT

On July 1, 2021, Kiromic BioPharma, Inc. entered into an Executive Agreement (the Ryan Agreement) with Dr. Michael Ryan to be its Chief Technology Officer (CTO). The term of the Ryan Agreement commenced on July 1, 2021 and will continue until the earlier of (i) July 1, 2024 or (ii) termination by either the Company or Dr. Ryan. Pursuant to the Ryan Agreement, Dr. Ryan’s base compensation will be $200,000 per year.

Latest news about Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Apr. 30	CI
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	Apr. 24	CI
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	Apr. 02	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Apr. 01	CI
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	Mar. 19	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	Feb. 14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Feb. 11	CI
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	Jan. 29	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Jan. 07	CI
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	Jan. 05	CI
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	Dec. 14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Dec. 11	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	Nov. 09	CI
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23-10-23	CI
Kiromic Biopharma, Inc. Appoints Brian Hungerford as Chief Financial Officer	23-10-03	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	23-09-26	CI
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from S&P TMI Index	23-09-18	CI
Kiromic Biopharma Shares Suspended From Trading on Nasdaq	23-09-14	MT
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index	23-09-13	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	23-08-24	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	23-07-24	CI

Chart Kiromic BioPharma, Inc.

Duration

Period

More charts

Company Profile

Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIROMIC BIOPHARMA, INC.	+217.24%	3.56M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+0.76%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-5.52%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs